Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 41, Issue -, Pages 39-46Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2016.05.011
Keywords
-
Categories
Funding
- National Institutes of Health [AI060354, AI095985, AI096040, AI100663, AI124377, OD011170]
- Bill and Melinda Gates Foundation
- Ragon Institute of MGH, MIT, and Harvard
Ask authors/readers for more resources
With 2 million people newly infected with HIV-1 in 2014, an effective HIV-1 vaccine remains a major public health priority. HIV-1 vaccine efficacy trials in humans, complemented by active and passive immunization studies in non-human primates, have identified several key vaccine-induced immunological responses that may correlate with protection against HIV-1 infection. Potential correlates of protection in these studies include V2-specific, polyfunctional, and broadly neutralizing antibody responses, as well as effector memory T cell responses. Here we review how these correlates of protection are guiding current approaches to HIV-1 vaccine development. These approaches include improvements on the ALVAC-HIV/AIDSVAX B/E vaccine regimen used in the RV144 clinical trial in Thailand, adenovirus serotype 26 vectors with gp140 boosting, intravenous infusions of bNAbs, and replicating viral vectors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available